-
Adverse Effects Influence Patient’s Perspective of Ocrevus’s Effectiveness, Survey Shows
Higher rates of adverse effects have a negative impact on a patient’s perspective about treatment with Ocrevus (ocrelizumab), according to a survey conducted by the multiple sclerosis community GeneFo.
About half of the 840 patients surveyed so far have reported improvements from Ocrevus. Those reporting none had a higher rate of adverse effects, a finding highlighting the importance of doctors managing the therapy’s side effects.
The U.S. Food and Drug Administration approved Ocrevus, which was developed by Genentech, on March 28, 2017. It was a landmark decision, because Ocrevus became the first treatment approved for both the relapsing and progressive forms of MS.
Now, a year after the approval, GeneFo asked patients about their experiences with Ocrevus.
“There has been such a buzz in the MS community, and on our platform in particular, about Ocrevus, which is completely natural as patients are discovering in real-time the effects of a new disease-modifying therapy,” Neer Ziskind, GeneFo’s CEO, said in a news release provided to Multiple Sclerosis New Today. “People who began treatment were happy to share from their experience, and potential Ocrevus users were of course eager to learn from their peers and get advice on how to best adapt to this new medication.”
Read more about Ocrevus here: “Adverse Effects Influence Patient’s Perspective of Ocrevus’s Effectiveness, Survey Shows“
Have you tried Ocrevus? Share your experience below.
-
0 Replies
Sorry, there were no replies found.
Log in to reply.